

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/038,516	01/03/2002	Tuan Bui	IDB-5775 (1417G P 645) 6007	
7590 08/25/2004			EXAMINER	
Francis C.M. Kowalik, Esq.			MAIORINO, ROZ	
Corporate Counsel, Law Department BAXTER INTERNATIONAL INC.			ART UNIT	PAPER NUMBER
One Baxter Parkway, DF2-2E			3763	
Deerfield, IL 60015			DATE MAILED: 08/25/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/038,516	BUI, TUAN				
Office Action Summary	Examiner	Art Unit				
·	Roz Maiorino	3763				
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the o	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a repl If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE.	mely filed ys will be considered timely. In the mailing date of this communication. ED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 12 A	pril 2004.					
,						
Disposition of Claims						
4) ⊠ Claim(s) <u>1-41</u> is/are pending in the application 4a) Of the above claim(s) <u>3,10,13-19,21,22 and</u> 5) ☐ Claim(s) is/are allowed. 6) ⊠ Claim(s) <u>1,2,4-8,11,12,20,23,24,40 and 41</u> is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	<u>d 25-39</u> is/are withdrawn from co are rejected.	nsideration.				
Application Papers		,				
9) The specification is objected to by the Examine	er.					
10) The drawing(s) filed on is/are: a) acc	cepted or b) objected to by the	Examiner.				
Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E						
Priority under 35 U.S.C. § 119						
a) ☐ Acknowledgment is made of a claim for foreign a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority document 2. ☐ Certified copies of the priority document 3. ☐ Copies of the certified copies of the priority document application from the International Bureat * See the attached detailed Office action for a list	ts have been received. ts have been received in Applicat ority documents have been receiv u (PCT Rule 17.2(a)).	tion No red in this National Stage				
Attachment(s)	4) 🔲 Interview Summar	v (PTO-413)				
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 	Paper No(s)/Mail C					

Art Unit: 3763

DETAILED ACTION

Since applicants response to the non-final rejection was incorrectly entered as an after-final response, the advisory is being withdrawn and replaced by a final rejection.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

1. Claims 1-2, 4-8, 11-12, 20, 23-24, 40-41 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent Pub No.6562001 to Lebel et al.

Lebel teach a medical device having a supply of medication and a means for delivering the medication to the patient, a control algorithm coupled to the medical device, and a sensor coupled to a patient to receive information from the patient concerning the physiological condition of the patient, the information being transferred from the sensor to the control algorithm, wherein the control algorithm is adapted to process the information to control the delivery of the medication form the medical devote to the patient base on the information that was processed. (see paragraphs, 23, 40, 55, 63, 72, 77, 119, 298, 289 and the entire reference.)

2. Claims 4-8, 11-12, 20, 23-24, 40-41 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No.5978702 to Ward et al or US Patent No. 5474552 to Palti.

Ward or Palti both teach a medical device having a supply of medication and a means for delivering the medication to the patient, a control algorithm coupled to the medical device, and a sensor coupled to a patient to receive information from the patient concerning the physiological condition of the patient, the information being transferred from the sensor to the control algorithm, wherein the control algorithm is adapted to process the information to control the delivery of the medication form the medical devote to the patient base on the information that was processed.

Art Unit: 3763

Double Patenting

Page 4

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. Claims 1-2, 4-8, 11-12, 20, 23-24, 40-41 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-23 of copending Application No. 10039751. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims in the current application are simply a broader claim limitations than the claims in Application No. 1039751.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Response to Arguments

4. Applicant's arguments filed 4/12/2004 have been fully considered but they are not persuasive. Applicant claims the Label does not teach a sensor coupled to a patient, however Label teaches a sensor implanted into the patient.

5. Applicant's arguments with respect to claims 4-8, 11-12, 20, 23-24, 40-41 have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Roz Maiorino whose telephone number is 703-305-2336. The examiner can normally be reached on 9am-5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on 703-308-3552. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/038,516

Art Unit: 3763

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Page 6

RM